arrow
Y

Yukari Okubo

Tokyo Medical University
H指数:30
被引数:3,335

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Efficacy of Apremilast in Patients with Psoriasis with Limited Skin Involvement, Including High-Impact Site Involvement: A Pooled Analysis of Six Trials

阿普米ast在皮肤受累范围有限且包括重要部位受累的银屑病患者中的疗效:六项试验的合并分析

2026-10-020
OA
Safety and Efficacy of Deucravacitinib in Japanese Patients With Moderate to Severe Plaque Psoriasis: 5-Year Analysis of the Phase 3 POETYK PSO-1, PSO-4, and Long-Term Extension Trials

德库拉伐替尼在日本中重度斑块状银屑病患者中的安全性和有效性:III期POETYK PSO-1、PSO-4试验及长期扩展试验的5年分析

2026-09-210
OAAI
Regulation of Imiquimod-Induced Mouse Psoriasis Development via Apoptosis Signal-Regulating Kinase 1 Potentially by Antagonizing Aryl Hydrocarbon Receptor Expression

咪喹莫特诱导的小鼠银屑病发生通过凋亡信号调节激酶1的调节,可能通过拮抗芳烃受体表达

2026-06-250
OA
Treatment Guidance for Palmoplantar Pustulosis 2022

2022年掌跖脓疱病治疗指南

2026-06-070
OAAI
Summary of Research: Apremilast in Japanese Patients with Palmoplantar Pustulosis: A Randomized, Phase 3 Trial

研究摘要:Apremilast在日本掌跖脓疱病患者中的疗效:一项随机、III期临床试验

2025-12-130
OAAI
Apremilast in Japanese patients with palmoplantar pustulosis: A randomized, Phase 3 trial

Apremilast在日本掌跖脓疱病患者中的疗效:一项随机、III期临床试验

2025-11-260
OAAI
Efficacy and Safety of Bimekizumab in Japanese Patients with Generalised Pustular Psoriasis and Erythrodermic Psoriasis: 3-Year Results from BE BRIGHT, a Multicentre, Open-Label, Phase 3 Study

贝美克单抗在日本泛发性脓疱型银屑病和红皮病型银屑病患者中的疗效与安全性:来自一项多中心、开放标签、III期研究BE BRIGHT的3年结果

2025-08-110
OA
Clinical Characteristics and Safety Profiles of Japanese Psoriasis Patients Who Continued Apremilast Treatment for 6 and 12 Months: A Post Hoc Analysis of an Apremilast Postmarketing Surveillance Study

日本银屑病患者在继续接受阿普米酯治疗6个月和12个月后的临床特征与安全性特征:一项阿普米酯上市后监测研究的回顾性分析

2025-05-100
OA
Deucravacitinib, an Oral, Selective, Allosteric Tyrosine Kinase 2 Inhibitor, in Japanese Patients With Plaque Psoriasis: In-Depth Analysis of Efficacy and Safety in the Phase 3 POETYK PSO-4 Trial

德库拉瓦西尼布,一种口服、选择性、别构酪氨酸激酶2抑制剂,在日本斑块状银屑病患者中的应用:对第3期POETYK PSO-4试验中疗效和安全性的深入分析

2025-04-300
OAAI